Key facts
- This page summarizes Pascal Touchon's Form 4 filing for Atara Biotherapeutics, Inc. (ATRA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Aug 2023, 18:25.
Pascal Touchon - 16 Aug 2023 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- ATRA
- Reported as of
- 16 Aug 2023
- Net transaction value
- -$50,835
- SEC form
- 4
- Accepted by SEC
- 18 Aug 2023, 18:25:18 UTC
- Prior SEC filing
- 29 Jun 2023
- Next SEC filing
- 20 Nov 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeff Kiekhofer, Attorney-in-Fact for Pascal Touchon
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pascal Touchon filed Form 4 for Atara Biotherapeutics, Inc. (ATRA) on 18 Aug 2023.
Change
- Previous filing in this sequence was filed on 29 Jun 2023.
- Current net transaction value: -$50,835.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ATRA
transaction
Common Stock
Sale
- Transaction value
- $35,406
- Shares
- -21,432
- Change %
- -3%
- Price
- $1.65
- Shares after
- 685,239
- Date
- 16 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F2
ATRA
transaction
Common Stock
Sale
- Transaction value
- $15,429
- Shares
- -9,334
- Change %
- -1.4%
- Price
- $1.65
- Shares after
- 675,905
- Date
- 16 Aug 2023
- Ownership
- Direct
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Shares sold automatically to satisfy tax withholding obligations in connection with the vesting of previously granted restricted stock units, pursuant to a sale-to-cover provision in the award agreement.
Footnote F2
The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2023 and August 17, 2023 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.